Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03457948 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases
A Phase 2 study of Metastatic Malignant Neoplasm in the Liver and Neuroendocrine Neoplasm, sponsored by Nicholas Fidelman, MD.
- Active
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT03457948 is a Phase 2 study of Metastatic Malignant Neoplasm in the Liver and Neuroendocrine Neoplasm that is active but no longer recruiting, run by Nicholas Fidelman, MD. The registered enrollment target is 32 participants, below the 90-participant average among 13 other Metastatic Malignant Neoplasm in the Liver trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03457948, a Phase 2 study of Metastatic Malignant Neoplasm in the Liver and Neuroendocrine Neoplasm, is active but no longer recruiting, sponsored by Nicholas Fidelman, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot phase II trial studies how effective pembrolizumab and liver-directed therapy or peptide receptor radionuclide therapy are at treating patients with well-differentiated neuroendocrine tumors and symptomatic and/or progressive tumors that have spread to the liver (liver metastases). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Liver-directed therapies such as radiofrequency ablation, transarterial embolization, yttrium-90 microsphere radioembolization, and cryoablation may help activate the immune system in order to shrink tumors that are not being directly targeted. Peptide receptor radionuclide therapy is a form of targeted treatment that is performed by the use of a small molecule, which carries a radioactive component attached to a peptide. Once injected into the body, this small molecule binds to some specific sites on tumor cells called receptors and emit medium energy radiation that can destroy cells. Because this radionuclide is attached to the peptide, which binds receptors on tumor lesions, the radiation can preferably be targeted to the tumor cells in order to destroy them. Giving pembrolizumab in combination with liver-directed therapy or peptide receptor radionuclide therapy may work better than pembrolizumab alone.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- PROCEDURE Arterial Embolization
- BIOLOGICAL Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate
- DEVICE Yttrium-90 Microsphere Radioembolization
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2018-08-27 |
| Est. Completion | 2026-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03457948
The ClinicalTrials.gov registry entry for NCT03457948 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 90-participant average among 13 other Metastatic Malignant Neoplasm in the Liver trials with a reported enrollment target (64% lower). The listed sponsor is Nicholas Fidelman, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Malignant Neoplasm in the Liver appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT03457948 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03457948 about?
NCT03457948 is a clinical study titled "Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases". This pilot phase II trial studies how effective pembrolizumab and liver-directed therapy or peptide receptor radionuclide therapy are at treating patients with well-differentiated neuroendocrine tumors and symptomatic and/or progressive tumors that have spread to the liver (liver metastases). Immuno...
What is the current status of trial NCT03457948?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2018-08-27. Estimated completion is 2026-05-31.
What conditions does trial NCT03457948 study?
This clinical trial studies the following conditions: Metastatic Malignant Neoplasm in the Liver, Neuroendocrine Neoplasm.
What interventions are being tested in trial NCT03457948?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Arterial Embolization (PROCEDURE), Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate (BIOLOGICAL), Yttrium-90 Microsphere Radioembolization (DEVICE).
Who is sponsoring clinical trial NCT03457948?
This trial is sponsored by Nicholas Fidelman, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03457948 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Malignant Neoplasm in the Liver
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Short Stitch Versus Traditional Suture for the Prevention of Incisional Hernia After Open Hepatectomy
RECRUITING · Phase 2
-
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
RECRUITING · Phase 2
-
Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases
ACTIVE NOT RECRUITING · Phase 2
-
Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
RECRUITING · Phase 1
-
An Investigational Scan (Intravoxel Incoherent Motion Diffusion Weighted Imaging) for the Evaluation of Colorectal Cancer Liver Metastases Treatment Response
RECRUITING · NA
Explore more on PlainTrial
Metastatic Malignant Neoplasm in the Liver
All registered trials for this condition
Neuroendocrine Neoplasm
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.